Trends in molecular medicine, 2022-04, Vol.28 (4), p.253-254
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- InFUSing antisense oligonucleotides for treating ALS
- Ist Teil von
- Trends in molecular medicine, 2022-04, Vol.28 (4), p.253-254
- Ort / Verlag
- England: Elsevier Ltd
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The question of a loss or toxic gain of function in FUS-related amyotrophic lateral sclerosis is still debated. Recently, Korobeynikov et al. argued that FUS mutations lead to a gain of function and showed that lowering wild-type and mutant FUS levels could be a promising therapeutic strategy.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1471-4914eISSN: 1471-499XDOI: 10.1016/j.molmed.2022.02.006Titel-ID: cdi_proquest_miscellaneous_2636143632
- Format
- –
- Schlagworte
- amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis - genetics, Amyotrophic Lateral Sclerosis - therapy, antisense oligonucleotide, DNA-Binding Proteins - genetics, DNA-Binding Proteins - metabolism, FUS, Humans, Mutation, Oligonucleotides, Antisense - genetics, Oligonucleotides, Antisense - therapeutic use, RNA-Binding Protein FUS - genetics, TDP-43